Ludovic Martinet

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Journal: Biomarker research
Published: May 24, 2026

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Journal: Clinical pharmacology and therapeutics
Published: March 07, 2026

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

Journal: Immunity
Published: January 21, 2025

Impact of the Multiple Sclerosis-Associated Genetic Variant CD226 Gly307Ser on Human CD8 T-Cell Functions.

Impact of the Multiple Sclerosis-Associated Genetic Variant CD226 Gly307Ser on Human CD8 T-Cell Functions.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: September 04, 2024

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Journal: Blood
Published: July 10, 2024

NK Cell Immaturity and NKp30 Expression Positively Correlate with Clinical Outcome in Multiple Myeloma Patients from the IFM2009 Clinical Trial.

NK Cell Immaturity and NKp30 Expression Positively Correlate with Clinical Outcome in Multiple Myeloma Patients from the IFM2009 Clinical Trial.

Journal: European journal of immunology
Published: April 15, 2024

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

Journal: Blood
Published: December 06, 2023

RAS/RAF landscape in monoclonal plasma cell conditions.

RAS/RAF landscape in monoclonal plasma cell conditions.

Journal: Blood
Published: August 22, 2023

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

Journal: Blood cancer journal
Published: August 21, 2023

TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

Journal: Immunity
Published: June 29, 2022

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

Journal: Blood
Published: May 06, 2021

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.

Journal: Blood advances
Published: October 28, 2020
Showing 1-12 of 36

Last Updated: 09/26/2026